Ontology highlight
ABSTRACT:
SUBMITTER: Borthakur G
PROVIDER: S-EPMC3702160 | biostudies-literature | 2008 Apr
REPOSITORIES: biostudies-literature
Borthakur Gautam G Ahdab Samih El SE Ravandi Farhad F Faderl Stefan S Ferrajoli Alessandra A Newman Beth B Issa Jean-Pierre JP Kantarjian Hagop H
Leukemia & lymphoma 20080401 4
Azacitidine and decitabine are the two hypomethylating agents approved by the Food and Drug Administration for the treatment of patients with myelodysplastic syndrome (MDS). The efficacy of one agent post-failure of the other is unknown. Fourteen patients with MDS post-azacitidine failure/lack of response/intolerance were treated with decitabine. Overall three patients achieved a complete remission, and one patient had hematologic improvement, for an overall response rate of 28%. Of the responde ...[more]